Evidence map›Paper›PMID 29029405›Full record

ArticleOncotarget2017

SOX7 promotes the maintenance and proliferation of B cell precursor acute lymphoblastic cells.

Sara Cuvertino, Genny Filiciotto, Ashish Masurekar, Vaskar Saha, Georges Lacaud, Valerie Kouskoff

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Sara CuvertinoCancer Research UK Manchester Institute, The University of Manchester, Manchester M20 4BX, UK.
Genny FiliciottoCancer Research UK Manchester Institute, The University of Manchester, Manchester M20 4BX, UK.
Ashish MasurekarChildren's Cancer Group, Institute of Cancer Sciences, The University of Manchester, Manchester M20 4BX, UK.
Vaskar SahaChildren's Cancer Group, Institute of Cancer Sciences, The University of Manchester, Manchester M20 4BX, UK.
Georges LacaudCancer Research UK Manchester Institute, The University of Manchester, Manchester M20 4BX, UK.
Valerie KouskoffCancer Research UK Manchester Institute, The University of Manchester, Manchester M20 4BX, UK.
Cancer Research UK Manchester Institute · GBUniversity of Manchester · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

B cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most frequent type of cancer in children. Despite progresses in curative treatment, intensive chemotherapy regimens still cause life threatening complications. A better understanding of the molecular mechanisms underlying the emergence and maintenance of BCP-ALL is fundamental for the development of novel therapies. Here, we establish that

Indexed as

B-ALLleukemiaSOX7

Identifiers

PMID29029405
PMCPMC5630305
OpenAlexW2462580843

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.